Spelling suggestions: "subject:"apos"" "subject:"apo""
61 |
Odor identification in aging and dementia : Influences of cognition and the ApoE geneOlofsson, Jonas January 2008 (has links)
Olfactory function is impaired in aging and dementia. The general aim of this thesis was to identify variables that predict olfactory function and dysfunction (assessed with an odor identification test) in middle-aged and elderly adults. The thesis investigated whether odor identification performance was associated with demographic variables, cognitive function, the ApoE gene, dementia, and other health-related variables. The ApoE-ε4 allele is associated with cognitive impairment and Alzheimer’s disease, the most common form of dementia. The studies included in this thesis used data from the Betula study, a large-scale, population-based prospective study on aging, memory, and health. Study 1 investigated demographic and cognitive predictors of odor identification ability in non-demented participants. The results showed that younger age, female sex, and high education contributed to better odor identification ability. Cognitive speed and vocabulary had a small additional influence. Study 2 included information about ApoE genotypes, dementia and other health-related variables. The results indicated that the ApoE-ε4 allele was associated with odor identification impairment among the elderly, but not middle-aged adults. Participants who were demented at the time of testing or became demented within five years after testing exhibited olfactory impairments. Interestingly, the age-related olfactory impairment in ε4-carriers was independent of clinical dementia within five years. In Study 3, decline in global cognitive status over a five-year test-retest interval was predicted in a sample of elderly participants. The major result was a three-way interaction reflecting that odor identification impairment, old age, in combination with the ε4 allele predicted a larger cognitive decline. However, odor identification impairment did not predict cognitive change in elderly who were non-carriers of the ε4 allele. Overall, the results indicate that odor identification impairment in elderly is related to ApoE-ε4, cognitive decline, and clinical and pre-clinical stages of dementia. Theoretical and practical implications of the results are discussed. Furthermore, it is proposed that in order to effectively predict clinical dementia or cognitive decline from olfactory assessment in the elderly, variables that mediate (e.g. neuropathology) or moderate (e.g. age) the associations between olfactory function, the ε4 allele, and dementia need to be further evaluated, preferably in studies using longitudinal assessment.
|
62 |
The Impact of Enriched environment on Lipid metaboilsm after Experimental StrokeKuric, Enida January 2009 (has links)
Stroke is the major cause of serious long-term disability with a sufficient acute treatment for only a very limited number of patients. Limited recovery of neurological functions occurs and can be elevated by a permissive post-stroke milieu. Housing animals in an enriched environment modulates regenerative mechanisms in the nonischemic peri-infarct area which might be an attractive target for pharmacological treatments to promote recovery. Upon ischemia, cellular lipids are released due to massive cell damage and free lipids significantly contribute to the progression of acute and delayed cell death. The aim of this study was to evalute the effect of enriched environment on lipid metabolism. In particular we characterize the activation of the transcription factor liver X receptor (LXR) in glial scar formation and regulation of cholesterol balance of relevance for functional recovery following stroke. Brain tissues from animals subjected to permanent occlusion of middle cerebral artery (pMCAo) were analysed for LXRα and β protein expression. We found an upregulation and an increased transcriptional activity of LXRβ in the peri-infarct area of rats housing in an enriched environment following pMCAO. Our data anticipate that enriched environment may have positive effects on lipid recycling in the ischemic hemisphere following experimental stroke.
|
63 |
Mechanics of Atherosclerosis, Hypertension Induced Growth, and Arterial RemodelingHayenga, Heather Naomi 2011 May 1900 (has links)
In order to create informed predictive models that capture artery dependent responses during atherosclerosis progression and the long term response to hypertension, one needs to know the structural, biochemical and mechanical properties as a function of time in these diseased states. In the case of hypertension more is known about the mechanical changes; while, less is known about the structural changes over time. For atherosclerotic plaques, more is known about the structure and less about the mechanical properties. We established a congruent multi-scale model to predict the adapted salient arterial geometry, structure and biochemical response to an increase in pressure. Geometrical and structural responses to hypertension were then quantified in a hypertensive animal model. Eventually this type of model may be used to predict mechanical changes in complex disease such as atherosclerosis. Thus for future verification and implementation we experimentally tested atherosclerotic plaques and quantified composition, structure and mechanical properties.
Using the theoretical models we can now predict arterial changes in biochemical concentrations as well as salient features such as geometry, mass of elastin, smooth muscle, and collagen, and circumferential stress, in response to hemodynamic loads. Using an aortic coarctation model of hypertension, we found structural arterial responses differ in the aorta, coronary and cerebral arteries. Effects of elevated pressure manifest first in the central arteries and later in distal muscular arteries. In the aorta, there is a loss and then increase of cytoskeleton actin fibers, production of fibrillar collagen and elastin, hyperplasia or hypertrophy with nuclear polypoid, and recruitment of hemopoeitic progenitor cells and monocytes. In the muscular coronary, we see similar changes albeit it appears actin fibers are recruited and collagen production is only increased slightly in order to maintain constant the overall ratio of ~55 percent. In the muscular cerebral artery, despite a temporary loss in actin fibers there is little structural change. Contrary to hypertensive arteries, characterizing regional stiffness in atherosclerotic plaques has not been done before. Therefore, experimental testing on atherosclerotic plaques of Apolipoprotein E Knockout mice was performed and revealed nearly homogenously lipidic plaques with a median axial compressive stiffness value of 1.5 kPa.
|
64 |
Relationships among APOE Genotypes, Inflammatory Markers, and Risk Factors among African Americans with Ischemic StrokeWadas, Theresa M. January 2015 (has links)
African Americans experience a disproportionate mortality, morbidity, and disability associated with ischemic stroke. Traditional risk factors offer some explanation for this finding, but novel risk factors have not been explored. APOE4 genotype, which is more prevalent in African Americans demonstrate a pro-inflammatory phenotype that may result in an exaggerated inflammatory response associated with ischemic stroke, resulting in worse outcomes. The purpose of this study was to examine relationships among APOE genotypes, inflammatory markers (CD11β, platelet leukocyte aggregates, IL-1β, IL-6, IL-8, and tissue necrosis factor alpha), the anti-inflammatory marker, IL-10, and risk factors (hypertension, diabetes type II, obesity, hyperlipidemia, and smoking) in African Americans at 3 days post stroke. Twenty five patients were enrolled with 12 patients in the APOE4 group and 13 patients in the non-APOE4 group. In the APOE4 group, 75% were male compared to 54% in the non-APOE4 group. The average age in the APOE4 group was 56.5 ± 9.0 compared to 66 ± 16.0 years in the non-APOE4 group. Females in the APOE4 group were younger with ages comparable to men. All participants had hypertension. Forty two percent of patients in the APOE4 group had two risk factors and 46% of patients in the non-APOE4 group had three risk factors. Major findings included 1) there were no statistical difference between inflammatory markers and APOE genotypes, and 2) the APOE4 carrier was not a predictor for overall inflammatory load among African Americans with ischemic stroke. The study was underpowered and small effect sizes were not sufficient to create statistical findings. This was the first study to examined APOE genotypes, inflammatory markers, and risk factors among African Americans with ischemic stroke. More studies are needed to not only investigate novel risk factors, but to also characterize inflammatory and genetic mechanisms with ischemic stroke and their associated outcomes among African Americans. Such studies may lead to primary and secondary prevention of ischemic stroke and reduce the health disparities associated with ischemic stroke among African Americans.
|
65 |
Είναι η διαμεσολαβούμενη από υποδοχέα κάθαρση της απολιποπρωτεΐνης Ε σημαντική για την εμφάνιση διατροφικά επαγόμενης παχυσαρκίας και δυσανεξίας στη γλυκόζη;Καλογεροπούλου, Χριστίνα 02 March 2015 (has links)
Η απολιποπρωτεΐνη Ε (apoE) είναι κύριο συστατικό των VLDL λιποπρωτεϊνών και
των υπολειμμάτων χυλομικρών και είναι υπεύθυνη για την απομάκρυνση των
αθηρογενετικών λιποπρωτεϊνών από την κυκλοφορία. In vivo και in vitro μελέτες
έχουν δείξει ότι μεταλλάξεις στην apoΕ που εμποδίζουν την πρόσδεση των
λιποπρωτεϊνών που περιέχουν την apoΕ στον υποδοχέα της LDL (LDLr), συνδέονται
με υψηλά επίπεδα χοληστερόλης στο πλάσμα και προκαλούν πρώιμη
αθηροσκλήρωση σε ανθρώπους και πειραματόζωα. Στον άνθρωπο υπάρχουν τρεις
κύριες φυσικές ισομορφές της apoE που ονομάζονται E2, E3, E4 και είναι
αποτέλεσμα μεταλλάξεων στα αμινοξικά κατάλοιπα 112 και 158. Προηγούμενες
μελέτες σε πειραματόζωα έχουν δείξει πως η apoE διαμεσολαβεί στην εμφάνιση
διατροφικά επαγόμενης παχυσαρκίας. Σκοπός της εργασίας είναι να αξιολογήσουμε
το ρόλο της κάθαρσης των λιποπρωτεϊνών που περιέχουν apoE μέσω του υποδοχέα
LDLr στην εμφάνιση παχυσαρκίας, καθώς οι ισομορφές Ε3, Ε4 έχουν πολύ
μεγαλύτερη συγγένεια για τον LDLr από την Ε2 ισομορφή. Τα πειραματόζωα που
χρησιμοποιήθηκαν ήταν πειραματικά ποντίκια αγρίου τύπου C57BL/6, ποντίκια με
καθολική έλλειψη στην apoE (apoE-/-
) και ποντίκια που εκφράζουν την ανθρώπινη
E2, E3, E4 ισομορφή αντίστοιχα. Τα πειραματόζωα τρέφονταν με δίαιτα δυτικού
τύπου για ένα χρονικό διάστημα 24 εβδομάδων ενώ παράλληλα πραγματοποιήθηκαν
βιοχημικές και μεταβολικές μελέτες. Παρατηρήσαμε πως τα ποντίκια που εκφράζουν
την apoE2, παρά την χαμηλή συγγένεια που έχουν ως προς τον LDLr, αύξησαν το
βάρος τους περισσότερο και εμφάνισαν υψηλότερες τιμές χοληστερόλης και
τριγλυκεριδίων στο αίμα σε σχέση με τις υπόλοιπες ισομορφές. Γεγονός που
αποδεικνύει πως η κάθαρση των λιπιδίων του αίματος δεν σχετίζεται με την εμφάνιση
παχυσαρκίας στα πειραματικά μοντέλα ποντικών. Αντίθετα οι δοκιμασίες ανοχής στη
γλυκόζη που πραγματοποιήθηκαν έδειξαν πως τα apoE3
+/+ ποντίκια εμφάνισαν τη
χειρότερη ανοχή στη γλυκόζη, ενώ οι apoE2
+/+
, apoE4
+/+ ομάδες ποντικών είχαν
στατιστικά παρόμοιες καμπύλες. Σύμφωνα με τα παραπάνω προκύπτει πως εμφάνιση
διαβήτη και διατροφικά επαγόμενης παχυσαρκίας είναι ανεξάρτητα πεδία που πρέπει
να μελετηθούν ξεχωριστά. / Apolipoprotein E (apoE) is a major component of VLDL and chylomicron remnants and is responsible for the removal of atherogenic lipoproteins from the circulation. In vivo and in vitro studies have shown that apoE mutations that prevent the binding of apoE-containing lipoproteins to LDLr, are associated with high plasma cholesterol levels and cause premature atherosclerosis in humans and animals. In humans, there are three main natural isoforms of apoE called E2, E3, E4 and is the result of mutations in amino acid residues 112 and 158. Given that previous animal studies have shown that apoE mediates the development of diet-induced obesity, the aim of this study was the evaluation of the role of apoE-containing lipoprotein's clearance by the LDLr in the development of obesity. Taking into account that the E3, E4 isoforms have higher LDLr affinity compared to the E2 isoform, we focused on the role of different apoE isoforms in these metabolic diseases. The animals we used in this study were apoE-deficient mice (apoE-/-), mice expressing human E2 (apoE2+/+), E3 (apoE3+/+), E4 (apoE4+/+) isoform and wild type C57BL/6 mice as a control group. The animals were fed western type diet for a 24-week period while biochemical and metabolic studies were performed. We observed that mice expressing apoE2, despite having low LDLr affinity, had higher body weight compared to C57BL/6 and exhibited higher plasma cholesterol and triglyceride levels compared to the other isoforms. This observation demonstrates that the clearance of blood lipids is not associated with obesity in experimental mouse models. Conversely, the glucose tolerance tests carried out showed that the apoE3+/+ mice had the worst glucose tolerance, followed by apoE4+/+ and the apoE2+/+ mice groups (apoE3+/+>>apoE4+/+≥apoE2+/+) suggesting that in case of glucose tolerance the clearance of apoE-containing lipoproteins may be a factor. Based on the above, diet-induced obesity and diabetes are, probably, independent fields that should be studied separately.
|
66 |
Pathophysiological Characterization of intra‐ and extracellularly aggregated Amyloid Peptides in DementiasSaul, Anika 25 June 2013 (has links)
No description available.
|
67 |
The Role of the Glucagon-like Peptide-1 Receptor in AtherosclerosisPanjwani, Naim 15 November 2013 (has links)
Objective: Glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to reduce atherosclerosis in non-diabetic mice. We hypothesized that treatment with GLP-1R agonists would reduce the development of atherosclerosis in diabetic Apoe-/- mice.
Results: Exendin-4 treatment (10 nmol/kg/day) of high-fat diet-induced glucose-intolerant mice for 22 weeks did not significantly reduce oral glucose tolerance (P=0.62) or HbA1c (P=0.85), and did not reduce plaque size at the aortic sinus (P = 0.35). Taspoglutide treatment for 12 weeks (0.4-mg tablet/month) of diabetic mice reduced body weight (P<0.05), food intake (P<0.05), oral glucose tolerance (P<0.05), intrahepatic triglycerides (P<0.05) and cholesterol (P<0.001), and plasma IL-6 levels (P<0.01); increased insulin:glucose (P<0.05); and unaltered oral lipid tolerance (P=0.21), plasma triglycerides (P=0.45) or cholesterol (P=0.92). Nonetheless, taspoglutide unaltered aortic atherosclerosis (P=0.18, sinus; P=0.19, descending aorta) or macrophage infiltration (P=0.45, sinus; P=0.26, arch).
Conclusions: GLP-1R activation in either glucose-intolerant or diabetic mice does not significantly modify the development of atherosclerosis.
|
68 |
The Role of the Glucagon-like Peptide-1 Receptor in AtherosclerosisPanjwani, Naim 15 November 2013 (has links)
Objective: Glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to reduce atherosclerosis in non-diabetic mice. We hypothesized that treatment with GLP-1R agonists would reduce the development of atherosclerosis in diabetic Apoe-/- mice.
Results: Exendin-4 treatment (10 nmol/kg/day) of high-fat diet-induced glucose-intolerant mice for 22 weeks did not significantly reduce oral glucose tolerance (P=0.62) or HbA1c (P=0.85), and did not reduce plaque size at the aortic sinus (P = 0.35). Taspoglutide treatment for 12 weeks (0.4-mg tablet/month) of diabetic mice reduced body weight (P<0.05), food intake (P<0.05), oral glucose tolerance (P<0.05), intrahepatic triglycerides (P<0.05) and cholesterol (P<0.001), and plasma IL-6 levels (P<0.01); increased insulin:glucose (P<0.05); and unaltered oral lipid tolerance (P=0.21), plasma triglycerides (P=0.45) or cholesterol (P=0.92). Nonetheless, taspoglutide unaltered aortic atherosclerosis (P=0.18, sinus; P=0.19, descending aorta) or macrophage infiltration (P=0.45, sinus; P=0.26, arch).
Conclusions: GLP-1R activation in either glucose-intolerant or diabetic mice does not significantly modify the development of atherosclerosis.
|
69 |
Genes to remember : imaging genetics of hippocampus-based memory functionsKauppi, Karolina January 2013 (has links)
In the field of imaging genetics, brain function and structure are used as intermediate phenotypes between genes and cognition/diseases to validate and extend findings from behavioral genetics. In this thesis, three of the strongest candidate genes for episodic memory, KIBRA, BDNF, and APOE, were examined in relation to memory performance and hippocampal/parahippocampal fMRI blood-oxygen level-dependent (BOLD) signal. A common T allele in the KIBRA gene was previously associated with superior memory, and increased hippocampal activation was observed in noncarriers of the T allele which was interpreted as reflecting compensatory recruitment. The results from the first study revealed that both memory performance and hippocampal activation at retrieval was higher in T allele carriers (study I). The BDNF 66Met and APOE ε4 alleles have previously been associated with poorer memory performance, but their relation to brain activation has been inconsistent with reports of both increased and decreased regional brain activation relative to noncarriers. Here, decreased hippocampal/parahippocampal activation was observed in carriers of BDNF 66Met (study II) as well as APOE ε4 (study III) during memory encoding. In addition, there was an additive gene-gene effect of APOE and BDNF on hippocampal and parahippocampal activation (study III). Collectively, the results from these studies on KIBRA, BDNF, and APOE converge on higher medial temporal lobe activation for carriers of a high-memory associated allele, relative to carriers of a low-memory associated allele. In addition, the observed additive effect of APOE and BDNF demonstrate that a larger amount of variance in BOLD signal change can be explained by considering the combined effect of more than one genetic polymorphism. These imaging genetics findings support and extend previous knowledge from behavioral genetics on the role of these memory-related genes.
|
70 |
Prevention of Cardiometabolic Disease in Familial HypercholesterolemiaAwan, Zuhier 11 1900 (has links)
L’hypercholestérolémie familiale (FH) est un désordre lipidique associé aux maladies cardiovasculaires les plus fréquentes. La FH est causée par des mutations dans les gènes LDLR, APOB et PCSK9. Toutefois, chez 20% des patients souffrant de FH, aucune mutation dans ces gènes n'a été détectée et ceci suggère que d’autres gènes seraient à l’origine de la FH. Actuellement, le seul traitement de la FH est une thérapie aux statines. En général les statines sont bien tolérées, cependant, une monothérapie ne permet pas d’atteindre des niveaux thérapeutiques acceptables et dans bien des cas, une thérapie combinée devient nécessaire. De plus, l’intolérance aux statines est présente dans environ 12% des patients. Dans les trois dernières décennies, la survie des patients avec la FH a augmentée de façon notoire mais on observe aussi l’apparition d’une calcification vasculaire sévère chez certains d’entre eux. Il est donc primordial de développer des nouvelles approches thérapeutiques afin de prévenir ces complications tardives.
Dans cette thèse doctorat, nous présentons l’étude d’une famille avec un phénotype de FH sévère non causé par des mutations dans les gènes LDLR, APOB et PCSK9. Par des études biochimiques et par séquençage d’ADN utilisant les technologies de nouvelle génération (NextGenSeq), nous avons découvert une mutation dans le gène de l’APOE (Leu167del). Ceci nous permet de proposer le gène codant pour l’APOE comme le 4e locus responsable de la FH (FH4). Par la suite, nous avons effectué deux études de cohortes chez les patients atteints de FH. Premièrement, dans l’étude JUPITER, nous avons démontré que la rosuvastatin augmente les niveaux sanguins de la protéine PCSK9 et ceci limiterait l’efficacité du traitement aux statines. Nous avons aussi étudié l’influence du mutant naturel R46L (perte de fonction de la PCSK9) dans la réponse aux statines. Deuxièmement, nous avons examiné les effets de la perte de fonction de la PCSK9 sur le profil cardiométabolique au sein d’une population pédiatrique. Nous avons déterminé que le génotype de l’APOE est déterminant dans ce profil cardiométabolique. Enfin, nous avons étudié la calcification vasculaire chez les patients atteints de FH. Cette calcification vasculaire progresse de façon indépendante des niveaux de cholestérol sérique et n’est pas associée aux anomalies de l’homéostasie du calcium. En utilisant des modèles murins, nous avons démontré que les souris Ldlr-/- et Tg(Pcsk9) développent des calcifications vasculaires semblables à celles observées chez l’homme. De plus, nous avons confirmé l’implication de la voie de signalisation LRP5/Wnt dans la pathophysiologie de la calcification artérielle. Avec une étude interventionnelle, nous avons trouvé que l’inhibition de l’interleukine 1β (IL-1β) diminue fortement l’apparition de calcifications vasculaire dans notre modèle murin.
En conclusion, nos études ont permis l’identification d’un nouveau gène impliqué dans la FH, ont démontré aussi que les statines augmentent les niveaux sériques de PCSK9 et que la perte de fonction de la PCSK9 altère le profil cardiométabolique. Enfin, nous avons établi que la calcification vasculaire représente une complication tardive chez les patients atteints de FH et que, dans notre modèle murin, la calcification vasculaire peut être retardée par l’inhibition d’IL-1β. Ces découvertes peuvent avoir d’importantes répercussions cliniques chez l’humain. / Familial Hypercholesterolemia (FH) is the most common lipoprotein disorder associated with premature cardiovascular disease. Mutations in the LDLR, APOB and PCSK9 genes cause the FH phenotype, but in 20% of FH patients, no mutations in these genes are identified, suggesting that mutations in other genes cause FH. Treatment with statins has been the cornerstone of therapy. While statins are generally well tolerated, statin intolerance is found in approximately 12% of patients. Furthermore, statin use may not allow reaching LDL-C goals and combination therapy is often required. Nevertheless, survival of FH patients over the past 3 decades has improved significantly. As FH patients live longer, severe vascular calcifications have been described as a late complication in these patients. Given the increased survival rate and late complications, novel approaches and therapies are needed.
In the present thesis we examined a kindred with a severe FH phenotype, where sequencing of candidate genes failed to identify a causal mutation. Through biochemical analysis and next-generation exome sequencing we report a mutation (Leu167del) within the APOE gene that identifies the 4th locus causing FH (FH4). Next, we performed two cohort-based studies. Firstly, in the JUPITER trial we report that 20mg rosuvastatin treatment increases PCSK9 levels by 30%, thereby possibly limiting the efficacy of statin therapy. Then we show the effect of a loss-of-function (LOF) mutation of PCSK9, p.R46L, on the response to rosuvastatin. Secondly, we report that two PCSK9 gene variants, p.R46L and insLEU, were more frequent in French Canadian individuals. We also report that the APOE genotype determine the metabolic risk profile in these mutations. Finally, we studied vascular calcifications in FH individuals. These calcifications appear to progress independently of cholesterol levels and are not associated with disturbances in calcium homeostasis. Using mouse models, we show that Ldlr-/- and Tg(Pcsk9) mice develop aortic calcifications similar to that observed in humans. Furthermore, the involvement of the LRP5/Wnt pathway in the pathogenesis of calcification is illustrated. In a proof-of-concept experiment, inhibiting the upstream pro-inflammatory cytokine IL-1β attenuates calcification in mice.
In conclusion, we have contributed to the identification of a novel locus responsible for FH, reported the increase in PCSK9 levels with a statins treatment and the associated altered cardiometabolic profile in PCSK9 LOF. Finally, we demonstrated that vascular calcifications represent a severe complication of FH that can be prevented by inhibiting IL-1β in a mouse model. The latter novel approach may have an important translational application in human.
|
Page generated in 0.028 seconds